Effect of bortezomib on proliferation, apoptosis and expression of bcl-2 family proteins in primary acute leukemia cells from elderly patients
Sun Qixin, Zhigang Zhu, Guiping Chen
Abstract
Sun Qixin, Zhigang Zhu, Guiping Chen
Abstract
Objective To study the anti-tumor effect and mechanism of bortezomib in primary acute leukemia cells from elderly patients.Methods Primary acute leukemia cells were treated with bortezomib 50-5000 nmol/L for 24-48 h,cell proliferation was analysed by MTT assay; apoptosis of primary acute leukemia cells was observed by fluorescence microscopy and flow cytometry; protein expression of bcl-2 and Bax was detected by Western blot.Results The cell viability was 90 % and 70 % when leukemia cells were treated with 50 and 5000 nmol/L bortezomib for 24 h,respectively.Meanwhile,cells showed (10.2±2.3) % and (13.3±3.3) % apoptosis.With prolonged treatment for 48 h,cell viability decreased to 86 % and 60 %,respectively,while the apoptosis rates were increased to(18.4±3.9) % and(20.7±3.7) %.Compared to the control group 0 nmol/L bortezomib,the differences were statistically significant (F =53.76,F =7.74,F =54.49,F =16.94,all P values < 0.05).With the increase of bortezomib concentration,the bcl-2 protein expression was decreased,while Bax was up-regulated.Conclusion Bortezomib can inhibit primary leukemia cells from elderly patients proliferation and induce apoptosis.The mechanism may be associated with the changes in bcl-2 family protein expression. Key words: Leukemia; Aged; Bortezomib; Cell proliferation; Cell apoptosis
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To study the anti-tumor effect and mechanism of bortezomib in primary acute leukemia cells from elderly patients.Methods Primary acute leukemia cells were treated with bortezomib 50-5000 nmol/L for 24-48 h,cell proliferation was analysed by MTT assay; apoptosis of primary acute leukemia cells was observed by fluorescence microscopy and flow cytometry; protein expression of bcl-2 and Bax was detected by Western blot.Results The cell viability was 90 % and 70 % when leukemia cells were treated with 50 and 5000 nmol/L bortezomib for 24 h,respectively.Meanwhile,cells showed (10.2±2.3) % and (13.3±3.3) % apoptosis.With prolonged treatment for 48 h,cell viability decreased to 86 % and 60 %,respectively,while the apoptosis rates were increased to(18.4±3.9) % and(20.7±3.7) %.Compared to the control group 0 nmol/L bortezomib,the differences were statistically significant (F =53.76,F =7.74,F =54.49,F =16.94,all P values < 0.05).With the increase of bortezomib concentration,the bcl-2 protein expression was decreased,while Bax was up-regulated.Conclusion Bortezomib can inhibit primary leukemia cells from elderly patients proliferation and induce apoptosis.The mechanism may be associated with the changes in bcl-2 family protein expression. Key words: Leukemia; Aged; Bortezomib; Cell proliferation; Cell apoptosis
Key concepts: Bortezomib, Apoptosis, Leukemia, Flow cytometry, Viability assay, Cancer research, Cell growth, MTT assay